Skip to main content
. 2023 Mar 27;9:45. doi: 10.1038/s41531-023-00489-x

Table 2.

Patients demography.

Patients cases Gender Age (yo) Weight (kg) Height (m) Duration of PD (y) Duration of dyskinesia (y) MDS-UPDRS MoCA Conv. LEDD (mg) Apo. LEDD (mg) FDS PTI PTT
no. 1 M 53 92 1.78 16 NA 59 27 175 480 18.1 7.3 1.1
no. 2 F 68 41 1.55 18 8 NA 25 1420 960 14.9 1.5 0.1
no. 3 M 72 75 1.70 7 5 16 27 1360 1500 10 0.4 0.6
no. 4 M 58 78 1.68 4 2 NA 30 250 192 6.5 6 1.3
no. 5 M 53 70 1.82 11 8 NA 27 1940 880 17.8 3.3 0.2
no. 6 M 73 91 1.81 17 6 17 NA 2578.5 720 12.9 3.6 0.1
no. 7 M 64 77 1.73 7 3 24 26 993.75 650 11.2 12 1.2
no. 8 M 70 73 1.64 13 5 NA 27 983.5 780 12.2 2.8 0.5

MDS-UPDRS is the total score obtained after evaluation with the Movement Disorder Society – Unified Parkinson’s disease Rating Scale. MoCA is the total score obtained after evaluation of the patient with the Montreal Cognitive Assessment scale. Conv. LEDD is the Levodopa Equivalent Daily Dose of conventional treatment; Apo. LEDD is the Levodopa Equivalent Daily Dose of Apomorphine delivered by pump. FDS, PTI and PTT are the summarized scores obtained with the PKG.

NA not available.